Biotechnology company Inotrem SA revealed on Tuesday the receipt of the US Food and Drug Administration (FDA) Fast Track designation for the nangibotide development programme for the treatment of septic shock.
According to the company, nangibotide, which Phase IIb has just been cleared by the US FDA, is a TREM-1 inhibitor peptide with the potential to restore appropriate inflammatory response, vascular function and improve post septic shock survival.
Septic shock is the ultimate complication of sepsis. The incidence of septic shock continuously raises and mortality remains elevated (35%) in developed countries. The therapeutic solution has the potential to become the first mechanism-based treatment for septic shock.
The company will commence its planned global multicentric Phase IIb study in septic shock patients later this year to demonstrate efficacy of nangibotide and bring a clinically relevant proof of clinical activity in septic shock patients. The study intends to validate a personalized medicine approach using soluble TREM-1 as potential companion diagnostic test to identify patients likely to benefit from nangibotide.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007